The program, a collaboration between Pitt’s Office of Innovation and Entrepreneurship (OIE) and the Office of the Senior Vice Chancellor for the Health Sciences, is part of the University’s larger initiative to bring ideas and discoveries identified in the lab closer to products and treatments for patients.

Awards are granted in amounts of up to $50K to test scientific hypotheses addressing unmet needs or challenges in human health and disease with a commercial endpoint.

The program is open to University faculty, postdocs, students, and staff in Pitt’s Schools of the Health Sciences and offers funding, community, and a simplified process to enter ideas into the commercialization pathway. By kickstarting the testing of ideas, Pitt.INC adds value to innovators and boosts their potential for successful commercialization and societal impact.

Eligible applications do not have an invention disclosure on file with OIE, or if you have submitted an invention disclosure, no patent applications have been filed.

About Pitt.INC

  • Pitt.INC is designed to test novel scientific hypotheses addressing unmet needs or challenges in human health and disease with a commercial endpoint.
  • Awards are granted in amounts ranging up to $50K for projects with timelines no longer than one year.
  • Awardees are required to actively engage with Pitt’s Office of Innovation and Entrepreneurship (OIE), regularly report on project progress, and leverage support from Pitt’s innovation and commercialization ecosystem. Communications include a project kickoff meeting, progress reports, update meetings, and a final report.
  • Funded projects will have 1-2 quantifiable technical/scientific milestones designed to validate or invalidate a commercially-targeted scientific hypothesis. The final milestone-based project plan is developed in collaboration with the Pitt.INC external review panel and are approved by the Pitt.INC Board.
  • Projects are expected to start within one month of the award date (pending any necessary regulatory approvals or purchasing contracts) and should have timelines no longer than 12 months. Applicants should ensure their timelines are appropriate for the proposed studies.
  • Funding is managed by the Office of the Senior Vice Chancellor for the Health Sciences (OSVCHS). Awardees will coordinate with OSVCHS on account administration.
  • During the Pitt.INC award period, awardees agree not to pursue any third-party sponsored research opportunities to support the funded technology. Awardees in noncompliance with this condition will be required to repay the full Pitt.INC award.

  • Pitt.INC is open to University members in Pitt’s Schools of the Health Sciences, including faculty, postdocs, students, and staff. Postdocs, students, and staff must identify a Pitt Schools of the Health Sciences faculty member to serve as the principal investigator.
  • Projects must be in a life sciences-related field and address an unmet need or challenge in human health and/or disease.
  • Funding should support the development or validation of intellectual property owned by the University.
  • No invention disclosure on file with OIE, or if you have submitted an invention disclosure, no patent applications filed. If a patent application has been filed on your technology, please view OIE’s other innovation funding programs that may be more suited to your project.
  • Projects must be unencumbered from other obligations that would prevent the University from moving forward with commercialization. Projects should be available for licensing and not subject to any pre-existing options, licenses, or corporate-sponsored research agreements.
  • Under certain circumstances, Pitt.INC funding may be used to advance ideas developed in collaboration with another research institution. Applicants are required to identify collaborators from other institutions in their application and discuss with the OIE prior to proposal submission.
  • Projects with funding from another source to complete the same work are not eligible.

  • Applications are accepted through Pitt InfoReady.
  • Eligible ideas are reviewed by the Pitt.INC Board for scientific merit, commercial potential, and program fit.
  • Select applications are connected to the Pitt.INC external review panel for project plan finalization.
  • Final project plans and budgets are reviewed by the Pitt.INC Board, and award decisions are made.

Funds from Pitt.INC may only be used for the direct costs of the activities outlined in the approved project plan and budget.

Eligible expenses include:

  • Lab supplies, research animals, prototyping supplies, fabrication or manufacturing expenses, and trial costs
  • Postdoc, student, and technician salary and fringe
  • Consultants, contract research organizations (CRO), and service providers. All providers are required to assign IP rights to the University prior to beginning work.
  • With prior approval from OIE, travel costs related directly to meeting an approved milestone.

Ineligible expenses include:

  • Faculty salary and fringe
  • Overhead/indirect costs
  • Tuition
  • Travel
  • Capital equipment
  • Computer equipment
  • Publication costs

  • At the end of the program, awardees are required to submit an invention disclosure to Pitt’s Office of Innovation and Entrepreneurship (OIE).
  • Awardees will discuss their invention disclosure with an OIE licensing manager and coordinate an intellectual property management plan.
  • Awardees will be connected to the larger innovation and commercialization ecosystem that exists at the University to drive their projects towards societal impact.

Contact

 

Alandra Kahl, PhD

Assistant Director, Innovation Funding and Program Management
afk56@pitt.edu

Previous Awardees

Silas Davidson (student)
Eric Lechman, PhD (faculty PI)
Assistant Professor of Medicine, Division of Malignant Hematology and Medical
Oncology, Department of Medicine, School of Medicine

Project Title: Rebuilding Neurons: A novel target as a therapeutic candidate in CTE

Summary: Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative
disease caused by repeated head trauma, with no current treatments targeting the
underlying dysfunction. This project proposes targeting a specific protein as a novel
therapeutic approach to restore neuronal integrity in CTE. Preliminary data suggest that
enhancing this protein may counteract neuronal damage and support central nervous
system function.

Smita Iyer, PhD
Associate Professor of Pathology, Division of Experimental Pathology, Department of
Pathology, School of Medicine

Project Title: Neuroimmune modulation for neurodegenerative therapy

Summary: Neurodegenerative diseases, including Alzheimer’s and HIV-associated
cognitive decline, are rapidly increasing and share a common driver: chronic
neuroinflammation. This project introduces a novel therapeutic platform to target
inflammation in the brain, promoting a neuroprotective and anti-inflammatory response.
Through modulation of central nervous system immune function, this approach offers a firstin-class solution across multiple neuroinflammatory conditions.

Bambang Parmanto, PhD
Professor and Chair, Health Information Management Department, School of Health
and Rehabilitation Sciences

Project Title: GeniX: Generative AI platform for personalized clinical certification exam

Summary: Clinical programs rely on national certification exams, but current test
preparation methods are time-intensive for faculty and lack personalized, data-driven
support for students. GeniX is an AI-powered platform that tailors practice questions and
tutoring based on individual student needs, aiming to improve exam pass rates. GeniX offers
a scalable, cost-effective solution for clinical education programs across multiple
healthcare disciplines.

Samer Zaky, DMD, PhD
Research Assistant Professor, Department of Oral and Craniofacial Sciences, School
of Dental Medicine

Project Title: Objective test for diagnosis of pulpitis

Summary: Root canal treatments often lead to long-term tooth loss, especially in
adolescents, due to unreliable diagnostics that fail to distinguish between reversible and
irreversible pulpitis. This project aims to develop an objective test of inflamed tooth pulp to
guide treatment decisions and preserve dental health. Using cutting-edge precise,
personalized diagnostics, this approach would revolutionize dental care by preserving tooth
vitality and reducing unnecessary root canals.

Vincent Yuan, MD, PhD
Research Assistant Professor, Department of Otolaryngology – Head & Neck Surgery,
School of Medicine

Project Title: Evaluating novel exosomes as a therapeutic candidate for Meniere’s Disease

Summary: Meniere’s disease is a chronic inner ear disorder characterized by vertigo, hearing
loss, and tinnitus, with no FDA-approved disease-modifying treatments. This project
proposes using a novel therapy to reduce proinflammatory signaling and restore inner ear
structural integrity. As a first-in-class therapy, this approach offers a more effective and safer
alternative to current symptom-focused treatments for an underserved patient population.

David Gau, PhD
Assistant Professor of Pathology, Division of Experimental Pathology, Department of
Pathology, School of Medicine

Project Title: Novel therapeutic strategy for chronic kidney disease

Summary: Chronic kidney disease (CKD) affects over 37 million U.S. adults and is
associated with multiple co-morbidities, creating a significant healthcare burden and
highlighting the need for more effective treatments. This project explores a novel therapeutic
approach to restore cellular function and slow CKD progression. This solution could lead to
a first-in-class therapeutic platform for treating CKD and other metabolic diseases.

Back to Top